Broze G J
Barnes-Jewish Hospital at Washington University School of Medicine, St Louis, MO 63110, USA.
J Thromb Haemost. 2003 Aug;1(8):1671-5. doi: 10.1046/j.1538-7836.2003.00391.x.
Tissue factor pathway inhibitor (TFPI) is a multivalent Kunitz-type proteinase inhibitor that produces factor (F)Xa-dependent feedback inhibition of the factor VIIa/tissue factor (FVIIa/TF) catalytic complex that is responsible for the initiation of coagulation. Since 1985, when Rapaport and colleagues reported that the lipoprotein fraction of plasma contained a FXa-dependent inhibitor of FVIIa/TF, myriad articles have established its biochemical structure, its mechanism of action, and its physiological importance. This brief personal account reviews historical studies that established the existence of the inhibitor and the events that led to its initial isolation.
组织因子途径抑制剂(TFPI)是一种多价的库尼茨型蛋白酶抑制剂,它对负责启动凝血的因子VIIa/组织因子(FVIIa/TF)催化复合物产生依赖于因子(F)Xa的反馈抑制。自1985年拉帕波特及其同事报道血浆脂蛋白部分含有一种依赖于FXa的FVIIa/TF抑制剂以来,大量文章阐述了其生化结构、作用机制及其生理重要性。这篇简短的个人述评回顾了证实该抑制剂存在的历史研究以及导致其最初分离的事件。